Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

Core Insights - Organovo Holdings, Inc. is a clinical stage biotechnology company focused on developing novel treatment approaches for inflammatory bowel disease (IBD), including ulcerative colitis [1] - The company's lead drug, FXR314, will be presented at The Liver Meeting, highlighting findings from the Phase 2 MASH study [1][2] - The presentation will take place on November 17, 2024, by Dr. Eric Lawitz from the Texas Liver Institute [2] Company Overview - Organovo is developing drugs that are effective in three-dimensional (3D) human tissues, which are candidates for drug development [3] - FXR314 is currently in Phase 2 investigation for inflammatory bowel disease and has potential applications in metabolic liver disease and oncology [3] - The company utilizes proprietary technology to create 3D human tissues that replicate key aspects of native human tissue [3]